Biostate Ai

biostate.ai →

+126%

est. 2Y upside i

HealthcareAI & MLSeries A

Rank

#276

Sector

Biotechnology, AI, Healthcare

Est. Liquidity

~4Y

Data Quality

Data: Medium

Biostate AI presents a strong upside opportunity driven by its innovative generative AI and patented, low-cost RNA sequencing technology in a high-growth precision medicine market.

Last updated: March 10, 2026

Bull (30%)+350%

Biostate AI's K-Dense platform, validated by Harvard and fueled by proprietary data from global partnerships (e.g., MGH, Narayana Health), becomes a dominant AI solution for precision medicine. This drives revenue beyond $150M by 2028, justifying a $540M+ valuation (4.5x current) at a premium revenue multiple, as it significantly accelerates drug discovery and personalized treatment.

Base (45%)+90%

Biostate AI successfully expands its affordable RNA sequencing services and gains solid traction with its K-Dense software, securing additional strategic partnerships. Revenue reaches $70M by 2028, leading to a $228M valuation (1.9x current) at a healthy revenue multiple, reflecting continued market penetration and product development in key disease areas like oncology and autoimmune diseases.

Bear (25%)-80%

Despite strong technology, high regulatory hurdles or intense competition from established players or new entrants with massive resources slow market adoption of K-Dense. Revenue growth stagnates below $30M by 2028, leading to a down round or acquisition at a significantly lower valuation, potentially $24M (0.2x current), wiping out most common stock value due to liquidation preferences.

Est. time to liquidity~4.0 years

Preference Stack Risk

high

Investors hold $20M in liquidation preferences ahead of common shareholders, based on the total funding to date.

Dilution Risk

high

As an early-stage company (Series A), Biostate AI will likely require additional funding rounds, leading to further dilution of existing equity holders.

Secondary Liquidity

none

No active secondary market or tender offers are expected for a Series A company at this stage.

Questions to Ask at the Interview

Strategic questions based on Biostate Ai's data — designed to show you've done your homework.

  • 1

    “How is Biostate AI strategically planning to navigate the high regulatory barriers and potential incumbent threats from major pharmaceutical companies as it scales its K-Dense platform globally?”

  • 2

    “With a hybrid revenue model, how do you foresee the balance between RNA sequencing services and proprietary AI software/licensing evolving over the next 2-3 years, and what are the key milestones for K-Dense adoption and monetization?”

  • 3

    “Given the Series A funding and the need for future capital, what is the company's long-term vision for a liquidity event, and how does the current equity structure support employee value creation in potential exit scenarios?”

Community

Valuation Sentiment

Our model estimates +126% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.